- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03160573
Controlling Oral Malodor by ClōSYS Oral Rinse
Efficacy of ClōSYS Oral Rinse Products in Human Subjects in Controlling Oral Malodor
Study Overview
Status
Conditions
Detailed Description
Study Design:
The products used in this study are: ClōSYS Alcohol-Free Oral Rinse (referred here as ClōSYS Unflavored Oral Rinse) and ClōSYS justRIGHT MILD MINT Oral Rinse (referred here as ClōSYS Flavored Oral Rinse). This is an in-vivo, eight-week, a single-center, randomized, double-blind (subject/investigator), 2-waycross-overdesign clinical study. There will be two independent groups. Each subject of each group will be crossed over to the other group within a same group after the washout period. Each group will have their own control group. In the first phase, 25 subjects (50%) of each group will randomly be assigned to the active group; the other 25 subjects will be assigned to the control group. In the second phase, the participants will be crossed over of group assignment. The Study will enroll 100 subjects, aged 21 to 65 years, with a slight to strong intrinsic oral malodor, as determined by a panel of trained odor judges calibrated and standardized using a range of standard odorants sufficient to reflect the different patterns of nose receptors.
Study Plan:
Subjects will receive verbal and written oral hygiene instructions, and either one bottle (16 oz. each) of ClōSYS Unflavored Oral Rinse, ClōSYS Flavored Oral Rinse- or Placebo Oral Rinse each week. Subjects will also receive measuring cups for dispensing the rinse and a diary log for recording usage (the Oral Hygiene Kit) for use during the treatment. After a 2-week wash out period, each subject will receive another bottle of oral rinse according to their group assignment. The rinse bottles will be weighed prior to dispensing the product. A product log will be maintained and the weights of the bottles will be documented at each visit.
Subjects will be instructed to rinse twice a day, each in the morning and in the evening, with 15 mL mouth rinse for 30 seconds. They will note in their patient's log the date and time of rinsing.
Subjects will be instructed to continue with their normal oral hygiene practices, including tooth brushing and flossing but omitting any use of oral rinses or mouthwashes except for the Study materials. The subjects also will be instructed not to use other non-study related products such as breath mints, lozenge, gums, etc. as well as refraining from elective dental procedures during the study period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has read, signed, and received a copy of the Informed Consent prior to Study initiation.
- Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified Study examinations.
- Subject is between the ages of 21 and 65 years of age, male or female.
- Subject has normal oral interior cheek wall tissues.
- Subject is in good general health as determined by medical history and clinical judgment that no severe or debilitating disease exists that would impede participation in the Study.
- Subject must have an average organoleptic intensity rating of at least 2.6 but maximum 4.5 on an intensity scale of 0-5.
Exclusion Criteria:
- Pregnant or nursing per subject report.
- Diagnosis of Xerostomia, including medication induced Xerostomia.
- Any oral or extraoral piercing that interferes with the ability to perform study procedures and/or clinical assessments in the mouth.
- Fixed or removable oral appliance, such as orthodontic brackets or retainer, partial or complete dentures.
- Have advanced periodontal disease or excessive gingival recession, per Investigator/Examiner discretion.
- A known allergy or sensitivity to products planned for use in this study.
- Unwillingness to abstain from all other oral hygiene products other than those prescribed for the duration of the study.
- Heavy deposits of calculus, either supragingival and/or subgingival, per Investigator/Examiner discretion.
- Have a history of severe transmittable infectious disease (hepatitis, HIV, tuberculosis).
- Have a medical or dental condition that would be unduly affected by participation in this study, per Investigator discretion.
- Any other condition that Principal Investigator would consider interfering with the study.
- Smokers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Test-Unflavored Rinse then Placebo Unflavored Rinse
Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,.
After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
|
Other Names:
|
ACTIVE_COMPARATOR: Test-Flavored Rinse then Placebo Flavored Rinse
Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
|
Other Names:
|
PLACEBO_COMPARATOR: Flavored Oral Rinse-Placebo then Test-Flavored Rinse
Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
|
Flavor-matched placebo rinse
|
PLACEBO_COMPARATOR: Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse
Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
|
Unflavored-matched placebo rinse
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Malodor as Measured by Organoleptic Score
Time Frame: Weekly for three weeks
|
A 6-level organoleptic score from 0 - 5 will be used.
Score of 0 indicating malodor cannot be detected and score of 5 indicating very strong malodor.
|
Weekly for three weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sushma Nachnani, Ph.D., University Health Resources Group, Inc.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- UHRG-RPR-Malodor-ADA-2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Malodor
-
Novozymes A/SCompletedOral MalodorUnited States
-
Rowpar Pharmaceuticals, Inc.Loma Linda UniversityCompletedOral Malodor
-
Procter and GambleCompletedOral MalodorUnited States
-
Riyadh Colleges of Dentistry and PharmacyCompleted
-
Hadassah Medical OrganizationCompletedHalitosis | Bad Breath | Oral MalodorIsrael
-
Hadassah Medical OrganizationCompleted
-
Fernanda Muñoz SepúlvedaSubvención Presidencial, Ministerio de Hacienda, Chile; Centro Interuniversitario... and other collaboratorsCompletedOral Health Knowledge | Oral Health Attitudes | Oral Health Self-efficacyChile
-
Lund University HospitalEnrolling by invitationMandibular Reconstruction | Oral Surgical Procedures | Surgery, OralSweden
-
Okan UniversityFethiye Cakmak Ozlu; Erol Aktunc; Ersan Ilsay KaradenizCompletedOral Hygiene | Orthodontic Appliances | Oral Health Training
Clinical Trials on ClōSYS® Unflavored Rinse
-
Rowpar Pharmaceuticals, Inc.Loma Linda UniversityCompletedOral Malodor
-
Rowpar Pharmaceuticals, Inc.CompletedPeriodontitis | GingivitisUnited States
-
Sunstar AmericasCompleted
-
Medical University of South CarolinaNeilMed PharmaceuticalsCompleted
-
University of FloridaNeilMed PharmaceuticalsWithdrawnRhinosinusitis
-
University of Southern CaliforniaWallace H. Coulter Foundation; Halyard HealthCompleted
-
Johnson & Johnson Consumer and Personal Products...CompletedDentin SensitivityUnited States
-
University of North Carolina, Chapel HillColgate PalmoliveTerminatedCoronavirus Infection | COVID19 | SARS CoV-2 InfectionUnited States
-
University Fernando PessoaCompletedDental Adhesives/Restorations PerformancePortugal
-
Johnson & Johnson Consumer and Personal Products...CompletedTooth StainUnited States